Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Janux Therapeutics, Inc. (JANX : NSDQ)

• Company Description    Janux Therapeutics Inc. is a biopharmaceutical company. It involved in developing novel T cell engager immunotherapies. Janux Therapeutics Inc. is based in LA JOLLA, Calif. Number of Employees: 81

• Price / Volume Information    Yesterday's Closing Price: $23.22 Daily Weekly Monthly 20 Day Moving Average: 638,747 shares Shares Outstanding: 59.17 (millions) Market Capitalization: $1,374.05 (millions) Beta: 2.86 52 Week High: $71.71 52 Week Low: $22.48 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -8.69% -12.04% 12 Week -2.40% -21.53% Year To Date -56.63% -58.84%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 10955 Vista Sorrento Parkway Suite 200 - San Diego,CA 92130 USA ph: 858-751-4493 fax: - investors@januxrx.com http://www.januxrx.com

• General Corporate Information    Officers David Campbell - President and Chief Executive Officer Ron Barrett - Chairperson of the Board of Directors Vickie Capps - Director Eric Dobmeier - Director Sheila Gujrathi - Director Peer Information Janux Therapeutics, Inc. (CORR.) Janux Therapeutics, Inc. (RSPI) Janux Therapeutics, Inc. (CGXP) Janux Therapeutics, Inc. (BGEN) Janux Therapeutics, Inc. (GTBP) Janux Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 47103J105 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/06/25 Share - Related Items Shares Outstanding: 59.17 Most Recent Split Date: (:1) Beta: 2.86 Market Capitalization: $1,374.05 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.53 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.28 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 7.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/06/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.36 Price/Cash Flow: - Price / Sales: 105.30 EPS Growth vs. Year Ago Period: -26.67% vs. Previous Quarter: -5.56% Sales Growth vs. Year Ago Period: -82.56% vs. Previous Quarter: -95.07% ROE 06/30/25 - - 03/31/25 - -9.29 12/31/24 - -9.22 ROA 06/30/25 - - 03/31/25 - -8.89 12/31/24 - -8.80 Current Ratio 06/30/25 - - 03/31/25 - 58.47 12/31/24 - 59.21 Quick Ratio 06/30/25 - - 03/31/25 - 58.47 12/31/24 - 59.21 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - -832.71 12/31/24 - -651.62 Book Value 06/30/25 - - 03/31/25 - 17.11 12/31/24 - 19.49 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©